| Musculoskeletal |
Rhabdomyolysis (severe muscle breakdown that can cause kidney damage) |
< 1 case per 10 000–50 000 patients per year |
Often accompanied by extreme muscle pain, weakness, dark urine; risk increases with high doses or drug interactions. |
| Hepatic |
Severe hepatic injury (liver inflammation or failure) |
< 1 case per 10 000–100 000 |
Liver enzyme elevations are common; dramatic rise may signal serious injury. |
| Dermatologic |
Stevens–Johnson syndrome, toxic epidermal necrolysis, severe cutaneous drug reactions (SCAR) |
< 1 case per 10 000–100 000 |
Presents with skin blistering, mucosal involvement, and systemic symptoms. |
| Renal |
Acute interstitial nephritis, acute renal failure |
< 1 case per 10 000–50 000 |
Usually presents with rising creatinine, rash, or eosinophilia. |
| Allergic |
Angioedema, anaphylaxis, severe hypersensitivity |
< 1 case per 10 000–50 000 |
Swelling of lips, tongue, face; may be life‑threatening. |
| Cardiovascular |
Rare cases of ischemic heart events (e.g., myocardial infarction) reported in specific sub‑groups |
< 1 case per 10 000 |
Often confounded by underlying risk factors. |
| Neurologic |
Transient cognitive changes (memory loss, confusion) |
< 1 % of patients |
Usually mild and reversible; rare reports of persistent cognitive decline. |
| Gastrointestinal |
Gallbladder disease (cholelithiasis, cholecystitis) |
< 1 % of patients |
Cholestatic liver injury or gallstones may occur. |
| Metabolic |
New‑onset type 2 diabetes |
< 1 % of patients |
Statins may modestly increase fasting glucose; risk higher in those with pre‑diabetes. |